Astria Therapeutics (ATXS) Price & Analysis

Compare

1,167 Followers

ATXS Stock Chart & Stats

$12.51

-$0.31(-3.58%)

At close: Jan 08 4:00 PM EST

$12.51

-$0.31(-3.58%)

Day’s Range― - ―

52-Week Range$3.56 - $12.72

Previous CloseN/A

Volume35.54K

Average Volume (3M)3.17M

Market Cap

$714.13M

Enterprise Value$294.35M

Total Cash (Recent Filing)$227.72M

Total Debt (Recent Filing)$4.46M

Price to Earnings (P/E)―

Beta1.81

Next Earnings

Mar 05, 2026

EPS Estimate

-0.55

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.55

Shares Outstanding57,084,840

10 Day Avg. Volume895,846

30 Day Avg. Volume3,173,100

Financial Highlights & Ratios

PEG Ratio0.17

Price to Book (P/B)1.57

Price to Sales (P/S)0.00

P/FCF Ratio-6.16

Enterprise Value/Market Cap0.41

Enterprise Value/Revenue416.92

Enterprise Value/Gross Profit416.92

Enterprise Value/Ebitda-2.20

Forecast

1Y Price Target

$20.00

Price Target Upside59.87% Upside

Rating ConsensusHold

Number of Analyst Covering9

EPS Forecast (FY)-2.11

Revenue Forecast (FY)$8.57M

Bulls Say, Bears Say

Bulls Say

Acquisition DealBioCryst Pharmaceuticals is acquiring Astria in a cash/stock deal representing an implied ATXS per share value of $13.00, equating to ~$700M in enterprise value.

Market ExpansionBioCryst intends to expand HAE franchise by adding ATXS's Phase 3 long-acting injectable navenibart into its HAE portfolio.

Strategic PartnershipsAstria's partnership with Kaken Pharmaceutical represents a strategic opportunity to broaden navenibart’s market reach and validate its potential as a first-in-class HAE therapy option.

Bears Say

Financial PerformanceThe net loss for Q3 2025 was $31.6M ($0.55/share), indicating a higher loss compared to Q3 2024.

Stock Rating AdjustmentBased on Astria's current share price versus the acquisition price, the rating is moved to Market Perform.

Strategic ChallengesBioCryst intends to seek strategic alternatives for STAR-0310 due to it not fitting within their rare disease strategy.

Astria Therapeutics News

Astria Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald downgraded Astria Therapeutics (ATXS) to Neutral from Overweight. Published first on TheFly – the ultimate source...

12d ago

ATXS

Astria Therapeutics announces final results from ALPHA-STAR trial

Astria Therapeutics (ATXS) announced results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2...

19d ago

ATXS

Astria Therapeutics Reports Q3 2025 Results and BioCryst Acquisition

Astria Therapeutics, Inc. ( ($ATXS) ) has released its Q3 earnings. Here is a breakdown of the information...

12d ago

ATXS

Astria Therapeutics: Hold Rating Amid Acquisition and Financial Stability with Future Growth Prospects

In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on Astria Therapeutics, with...

12d ago

ATXS

Is ATXS a Buy, Before Earnings?

Astria Therapeutics, Inc. (ATXS) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street...

15d ago

ATXS

Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment

Astria Therapeutics, Inc. (($ATXS)) announced an update on their ongoing clinical study. Astria Therapeutics, Inc. is conducting a...

28d ago

ATXS

Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment

Astria Therapeutics, Inc. (($ATXS)) announced an update on their ongoing clinical study. Astria Therapeutics, Inc. is conducting a...

28d ago

ATXS

Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward

Astria Therapeutics, Inc. (($ATXS)) announced an update on their ongoing clinical study. Astria Therapeutics, Inc. is currently conducting...

28d ago

ATXS

Astria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Astria Therapeutics (ATXS) to Neutral from Buy without a price target after the company agreed...

1M ago

ATXS

BioCryst price target raised to $26 from $24 at Cantor Fitzgerald

Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on BioCryst (BCRX) to $26 from $24 and...

1M ago

ATXS

BCRX

Astria Therapeutics downgraded to Neutral from Outperform at Wedbush

Wedbush downgraded Astria Therapeutics (ATXS) to Neutral from Outperform with a price target of $13, down from $28,...

1M ago

ATXS

BioCryst price target raised to $27 from $17 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on BioCryst (BCRX) to $27 from $17 and...

1M ago

ATXS

BCRX

Astria downgraded to Market Perform from Outperform at Citizens JMP

Citizens JMP downgraded Astria Therapeutics (ATXS) to Market Perform from Outperform without a price target afire after the...

1M ago

ATXS

BioCryst reinstated with a Buy at TD Cowen

TD Cowen reinstated coverage of BioCryst (BCRX) with a Buy rating and $30 price target. The firm is...

1M ago

ATXS

BCRX

ATXS FAQ

What was Astria Therapeutics’s price range in the past 12 months?

Astria Therapeutics lowest stock price was $3.56 and its highest was $12.71 in the past 12 months.

What is Astria Therapeutics’s market cap?

Astria Therapeutics’s market cap is $714.13M.

When is Astria Therapeutics’s upcoming earnings report date?

Astria Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 100 days.

How were Astria Therapeutics’s earnings last quarter?

Astria Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.159.

Is Astria Therapeutics overvalued?

According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Astria Therapeutics pay dividends?

Astria Therapeutics does not currently pay dividends.

What is Astria Therapeutics’s EPS estimate?

Astria Therapeutics’s EPS estimate is -0.55.

How many shares outstanding does Astria Therapeutics have?

Astria Therapeutics has 57,084,840 shares outstanding.

What happened to Astria Therapeutics’s price movement after its last earnings report?

Astria Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 0.32%.

Which hedge fund is a major shareholder of Astria Therapeutics?

Currently, no hedge funds are holding shares in ATXS

Astria Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.15%

Trailing 12-Months

Asset Growth

-24.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Astria Therapeutics

Astria Therapeutics (ATXS) is a biopharmaceutical company focused on discovering and developing therapies for rare and niche diseases. The company's core mission is to create transformative treatments that improve the lives of patients with unmet medical needs. Astria Therapeutics leverages deep scientific expertise to advance its pipeline of innovative drug candidates targeting specific disease mechanisms.

Astria Therapeutics (ATXS) Earnings & Revenues

Historic Earnings Reports

ATXS Stock 12 Month Forecast

Average Price Target

$20.00

▲(59.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","36":"$36","11.25":"$11.25","19.5":"$19.5","27.75":"$27.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,11.25,19.5,27.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.63,14.350769230769231,16.071538461538463,17.792307692307695,19.513076923076923,21.23384615384615,22.954615384615387,24.675384615384615,26.396153846153844,28.116923076923076,29.837692307692308,31.558461538461536,33.27923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.63,13.196923076923078,13.763846153846155,14.330769230769231,14.897692307692308,15.464615384615385,16.03153846153846,16.59846153846154,17.165384615384617,17.732307692307693,18.299230769230768,18.866153846153846,19.433076923076925,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.63,12.65846153846154,12.686923076923078,12.715384615384616,12.743846153846155,12.772307692307693,12.800769230769232,12.829230769230769,12.857692307692307,12.886153846153846,12.914615384615384,12.943076923076923,12.971538461538461,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >